R. D. Soloway, M.D.; W. H. J. Summerskill, M.D., F.A.C.P.; A. H. Baggenstoss, M.D.; L. J. Schoenfield, F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
To define the features of "lupoid" hepatitis, we analyzed data from 88 consecutive patients with chronic active liver disease, selected prospectively by precisely predefined clinical, biochemical, and histologic criteria (Gastroenterology 60:167, 1971) and without reference to the result of the lupus erythematosus (LE) test. All were then randomized to treatment with prednisone, azathioprine, or both, or placebo. Therefore, our 6-monthly reevaluation included standard tests and liver biopsy. Initially, 30 patients were positive (LE+) and 58 negative (LE-). The LE+ patients were characterized significantly (P < 0.05) by disease of shorter duration—more frequent hepatomegaly and splenomegaly; higher serum bilirubin, serum glutamic-oxalacetic
R. D. Soloway, W. H. J. Summerskill, A. H. Baggenstoss, L. J. Schoenfield. Lupoid Hepatitis: A Nonentity in the Spectrum of Chronic Active Liver Disease?. Ann Intern Med. 1972;76:861. doi: 10.7326/0003-4819-76-5-861_2
Download citation file:
Published: Ann Intern Med. 1972;76(5):861.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use